Lijek koji se koristi za alkoholizam može liječiti rak ciljanjem na makrofage
Istraživačka grupa koju je vodio Yuya Terashima sa Sveučilišta u Tokiju otkrila je da lijek koji se koristi za alkoholizam može liječiti Raka ciljanjem na makrofage.
Prema podacima WHO-a i Međunarodne agencije za istraživanje raka (IARC), u 18.1. bilo je 9.6 milijuna novih slučajeva i 2018 milijuna smrtnih slučajeva. Jedan od 5 muškaraca i jedna od 6 žena diljem svijeta razviju rak tijekom života, a jedan od 8 muškaraca i jedna od 11 žena umre od ove bolesti. Diljem svijeta, ukupan broj ljudi koji prežive unutar 5 godina od dijagnoze raka, što se naziva 5-godišnja prevalencija, procjenjuje se na 43.8 milijuna.
Rak pluća je najčešća vrsta raka kod muškaraca (14.5%) i vodeći uzrok smrti kod muškaraca (22%). Nakon toga slijedi Rak prostate (13.5%), Rak debelog crijeva (10.9%), & rak jetre (9.5%). Među ženama, rak dojke iznosi približno 25%, a slijede rak pluća (13.8%), kolorektalni rak (9.5%) i rak vrata maternice (6.6%).
Building up a treatment to battle malignant growth remains one of the most troublesome difficulties in medicinal research. Malignant growth owes its infamous personality to the way that the disease cells utilize the host’s own resistant framework to develop and spread, finally getting savage. Invulnerable cells like macrophages, which usually battle to ensure ordinary cells, are commandeered by dangerous disease cells, and populate the earth around the tumors, turning out to be tumor-related macrophages (TAMs).
Zapravo, otkriveno je da je maligno tkivo pacijenata za koje imunoterapija nije bila plodna, zapravo je bila bogata makrofagima, potvrđujući vezu između bolesti i TAM-ova. Upravo ti TAM-ovi proizvode zastavice proteine poput kemokina i pokreću inhibicijsko otporna pražnjenja kontrolnih točaka koja čine imunosupresivni tumor condition, which ensures the malignant growth cells and permits their quickened development. Since the TAMs encourage the spreading of malignant stanice rasta, managing them as a remedial methodology for battling disease has picked up consideration as of late.
A research team from the Tokyo University of Science, under the direction of Yuya Terashima saw this as an opportunity to look into the field of developing new anti-malignant growth drugs. Their original work in Nature Immunology 2005 revealed the disclosure of another objective protein called FROUNT, which is connected to the guidelines and development of the TAMs. In this way, FROUNT was directly linked to TAM rules because it increased “chemokine signaling,” a type of cell communication that is necessary for TAM gathering and movement.
At that point, so as to diminish any symptoms, the group additionally built up an autonomous technique for restricting the impact of FROUNT on chemokine motion by repressing the connection between the two. The group screened 131,200 mixes and focused on disulfiram, a medication used to treat liquor abuse, and referred to for its potential as an enemy of malignant growth tranquilizer. This medication was found to legitimately tie to the FROUNT site, making FROUNT inaccessible for collaboration with the parts of chemokine flagging.
Considering the outcomes, Terashima clarifies, “When tried on mice, disulfiram repressed the development of macrophages and stifled the development of malignant growth cells. Thus, our findings reveal a new way to treat cancer that can stop the growth of cancer cells that are hard for immune systems to detect when used together with disulfiram.
Hopefully, we will get to see new therapies in the treatment of cancer.
